There were 440 press releases posted in the last 24 hours and 203,709 in the last 365 days.

GSK announces expiration of Hart-Scott-Rodino waiting period for tender offer for HGS


Issued: Friday 01 June 2012, London UK

GlaxoSmithKline plc (LSE: GSK) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976 (the “HSR Act”), as amended, has expired with respect to GSK’s tender offer for all the outstanding shares of Human Genome Sciences (NASDAQ: HGSI).  Accordingly, GSK has clearance under the U.S. anti-trust laws to acquire HGS, and the tender offer condition with respect to the expiration of the applicable waiting period under the HSR Act has been satisfied.

As previously announced, GSK commenced a tender offer on 10 May 2012 to acquire HGS for US$13.00 per share in cash.  The offer represents a premium of 81 percent to HGS's closing share price of US$7.17 on 18 April 2012, the last trading day before HGS publicly disclosed GSK’s private offer. The tender offer and withdrawal rights are scheduled to expire at 12:00 midnight New York City time on 7 June 2012.

Lazard and Morgan Stanley are acting as financial advisors to GSK and Cleary Gottlieb Steen & Hamilton and Wachtell, Lipton, Rosen & Katz are providing legal advice.

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com .